February 2, 2016 by CDR Blog
Adam Fein, Drug Channels Institute, Pembroke Consulting, pharmacy industry, specialty drugs
CDR Blog
Pharmaceutical supply chain and economics expert Adam Fein, CEO of the Drug Channels Institute, says specialty drugs continue to hoist pharmacy industry sales, according to his firm’s latest analysis. “We project that the pharmacy industry’s revenues will exceed $483 billion in 2020,” stated Fein, author of the 2016 Economic Report on Retail, Mail, and Specialty Pharmacies
November 9, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Alex Gourlay, chain drug retailing, CVS/pharmacy, Drug Channels Institute, George Fairweather, John Standley, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2015, Issue 11-09-2015, Issues, News
DEERFIELD, Ill. — The consolidation of chain drug retailing climaxed last month with Walgreens Boots Alliance Inc.’s (WBA’s) acquisition of Rite Aid Corp. In the largest outright purchase of a chain in the industry’s history, WBA agreed to acquire Rite Aid for $9 per share, or $17.2 billion, including debt. The price represents a premium
November 9, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Amy Klobuchar, B. Douglas Hoey, Drug Channels Institute, Federal Trade Commission, Mike Lee, National Community Pharmacists Association, Rite Aid, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2015, Issue 11-09-2015, Issues, News
DEERFIELD, Ill. — Walgreens Boots Alliance may have to divest up to 400 of the Rite Aid stores it is acquiring to satisfy antitrust regulations, analysts said. WBA is not publicly speculating on how many units it will have to shutter, said chief executive officer Stefano Pessina. “We have analyzed things very carefully,” he said
November 9, 2015 by John Schultz and Chain Drug Review
Adam Fein, CVS Caremark, Express Scripts, Jublia, OptumRx, Pembroke Consulting, Philidor Rx Services, Solodyn, Valeant Pharmaceuticals
2015, Issue 11-09-2015, Issues, News
NEW YORK — After CVS Caremark and two other pharmacy benefit managers announced that they are terminating mail-order pharmacy Philidor Rx Services LLC from their networks, Valeant Pharmaceuticals Inc. said it would also sever ties with Philidor. Philidor has been accused of bolstering sales of products made by the Canadian-based drug manufacturer Valeant. Joining CVS
July 6, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Brian Cornell, CVS Health, CVS/pharmacy, Drug Channels Institute, Larry Merlo, MinuteClinic, Pembroke Consulting, Target Corp., TargetExpress
2015, Issue 07-06-2015, Issues, News
WOONSOCKET, R.I. — Continuing its aggressive growth and diversification, CVS Health has purchased Target Corp.’s pharmacy and clinic businesses for some $1.9 billion. The acquisition propels CVS past Walgreens as the nation’s No. 1 pharmacy operator by market share and store count. CVS will have close to 9,500 prescription counters. Walgreens had 8,232 as of
February 13, 2015 by Chain Drug Review and Chain Drug Review
Adam Fein, CVS Health, Drug Channels, EnvisionRx, Fitch Ratings, PBM, Rite Aid
CDR Blog
Rite Aid’s acquisition of PBM EnvisionRx was seen by industry observers as a big plus for the drug chain. Fitch Ratings called the deal “a positive move as it will enable the company to expand its distribution channels by getting a foothold in the specialty and mail-order channels.” “The acquisition is supported by Rite Aid’s improved
January 28, 2015 by Chain Drug Review and Chain Drug Review
Adam Fein, Drug Channels Institute, specialty pharmaceutical, specialty pharmacy
CDR Blog
As in the retail pharmacy arena, the specialty pharmacy market is dominated by a small number of companies, noted the Drug Channels Institute, which has released its 2014-15 Economic Report on Retail, Mail, and Specialty Pharmacies. “The specialty pharmaceutical boom is reshaping the pharmacy industry’s market structure. Ten companies account for 70% of specialty pharmacy